PPBT (Purple Biotech) קצב צמיחת רווח למניה בשנה הנוכחית

Purple Biotech possesses significant market influence due to the uniqueness of the CM24 antibody. The annual earnings per share growth vector confirms this potential, with the 90.20 metric serving as the target level. Purple Biotech focuses on targeted therapy for resistant forms of cancer. Currently, the business is independently developing clinical trials while utilizing only contract manufacturing sites.

Investors frequently weigh the speculative interest in Purple Biotech (PPBT) against its actual profit generation efficiency. The annual earnings per share trajectory calculates the percentage shift in EPS relative to the previous year, demonstrating the dynamics of capital return per share. For this Israeli business, this trend reflects the ability to maintain operational resilience and scale profitability despite regional geopolitical instability.